Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding in Company

22 Sep 2017 14:01

RNS Number : 5998R
Silence Therapeutics PLC
22 September 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Silence Therapeutics plc

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Aviva plc & its subsidiaries

City and country of registered office (if applicable)

London, England

4. Full name of shareholder(s) (if different from 3.)v

Name

Registered Holder:

Chase (GA Group) Nominees Limited 2,651,683*

 

HSBC Global Custody Nominee (UK) Limited 651,949*

State Street Nominees Limited 50,617*

Available on Request 7,076*

*denotes direct interest

 

Chase (GA Group) Nominees Limited 119,537

 

Chase Nominees Limited 55,444

 

Vidacos Nominees Limited 156,300

 

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

20/09/2017

6. Date on which issuer notified (DD/MM/YYYY):

21/09/2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.28%

5.28%

69,991,624

Position of previous notification (if

applicable)

6.39%

6.39%

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary SharesGB00B9GTXM62

3,361,325

331,281

4.80%

0.48%

SUBTOTAL 8. A

3,692,606

5.28%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Aviva plc

5.28%

5.28%

Aviva Group Holdings Limited

5.28%

5.28%

Aviva Investors Holdings Limited

5.27%

5.27%

Aviva Investors Global Services Limited

5.27%

5.27%

Aviva plc

5.28%

5.28%

Aviva Group Holdings Limited

5.28%

5.28%

Friends Provident

International Limited

10. In case of proxy voting, please identify:

Name of the proxy holder

See Section 4

The number and % of voting rights held

The date until which the voting rights will be held

 

 

 

 

11. Additional informationxvi

This notification is prompted by a 5% to 4% change at Direct Interest Level (Box 8A)

 

Place of completion

Norwich, England

Date of completion

21 September 2017

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLPGURABUPMGPP
Date   Source Headline
28th Jun 20192:06 pmRNSAdditional Listing
25th Jun 201912:09 pmRNSResult of AGM
24th Jun 20191:20 pmRNSHolding(s) in Company
21st Jun 20192:36 pmRNSHolding(s) in Company
20th Jun 20191:36 pmRNSHolding(s) in Company
20th Jun 20191:00 pmRNSHolding(s) in Company
19th Jun 20199:16 amRNSHolding(s) in Company
18th Jun 20194:37 pmRNSHolding(s) in Company
18th Jun 20191:37 pmRNSHolding(s) in Company
18th Jun 201912:28 pmRNSAdditional Listing
28th May 20197:00 amRNSCollaboration with Genomics England
20th May 20194:46 pmRNSAdditional Listing
14th May 20193:00 pmRNSAdditional Listing
30th Apr 20197:00 amRNSAdditional Listing
26th Apr 20192:35 pmRNSAdditional Listing
25th Apr 20194:55 pmRNSAdditional Listing
25th Apr 20197:00 amRNSSilence Therapeutics Announces Board Changes
18th Apr 20197:00 amRNSAppointment of Chief Financial Officer
18th Apr 20197:00 amRNSSilence Therapeutics Publication of Annual Report
16th Apr 201911:00 amRNSSilence Therapeutics Announces Board Change
16th Apr 20197:00 amRNSSilence Therapeutics appoints Head of R&D and CMO
4th Apr 20199:09 amRNSHolding(s) in Company
27th Mar 20197:00 amRNSSilence Therapeutics submits CTA for SLN124
11th Mar 20197:00 amRNS2018 Preliminary Results
7th Mar 20197:00 amRNSSilence to Present at Cowen Healthcare Conference
5th Mar 20197:00 amRNSNotice of Results
4th Mar 20193:35 pmRNSHolding(s) in Company
26th Feb 20195:24 pmRNSHolding(s) in Company
1st Feb 20194:40 pmRNSSecond Price Monitoring Extn
1st Feb 20194:35 pmRNSPrice Monitoring Extension
15th Jan 20197:00 amRNSSLN124 granted Orphan Drug Designation by EMA
9th Jan 20197:00 amRNSDeparture of Chief Financial Officer
19th Dec 20187:00 amRNSSilence Therapeutics advances next RNAi medicine
18th Dec 20184:35 pmRNSPrice Monitoring Extension
10th Dec 20187:00 amRNSSettlement and License Agreement with Alnylam
12th Oct 20186:29 pmRNSErratum: Results of Placing - Withdrawn
12th Oct 20185:12 pmRNSResults of Placing
11th Oct 201810:14 amRNSPTAB Upholds Silence Patent
10th Oct 20187:00 amRNSNew divisional patent and injunction application
5th Oct 20182:16 pmRNSHolding(s) in Company
26th Sep 20187:00 amRNSSilence to Present at Healthcare Conference
21st Sep 20182:19 pmRNSAdditional Listing
11th Sep 20187:00 amRNSInterim results for six months ended 30 June 2018
30th Aug 201810:53 amRNSHolding(s) in Company
30th Aug 201810:46 amRNSHolding(s) in Company
24th Aug 20187:00 amRNSNotice of Results
20th Aug 20189:30 amRNSSilence Therapeutics Announces Board Change
7th Aug 20187:00 amRNSLitigation: patisiran EU MA imminent
17th Jul 20183:00 pmRNSDirector/PDMR Shareholding
17th Jul 20181:00 pmRNSAppoints David Horn Solomon as CEO

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.